These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26880366)

  • 21. Doubly robust inference for targeted minimum loss-based estimation in randomized trials with missing outcome data.
    Díaz I; van der Laan MJ
    Stat Med; 2017 Oct; 36(24):3807-3819. PubMed ID: 28744883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variance reduction in randomised trials by inverse probability weighting using the propensity score.
    Williamson EJ; Forbes A; White IR
    Stat Med; 2014 Feb; 33(5):721-37. PubMed ID: 24114884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Landmark Prediction of Long Term Survival Incorporating Short Term Event Time Information.
    Parast L; Cheng SC; Cai T
    J Am Stat Assoc; 2012; 107(500):1492-1501. PubMed ID: 23293405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment.
    Zhang M; Wang Y
    Biostatistics; 2012 Sep; 13(4):625-36. PubMed ID: 22510495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An improved method for the effect estimation of the intermediate event on the outcome based on the susceptible pre-identification.
    Hu H; Wang L; Li C; Ge W; Xia J
    BMC Med Res Methodol; 2021 Sep; 21(1):192. PubMed ID: 34548029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-parametric estimation and model checking procedures for marginal gap time distributions for recurrent events.
    Kvist K; Gerster M; Andersen PK; Kessing LV
    Stat Med; 2007 Dec; 26(30):5394-410. PubMed ID: 17994608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doubly-robust methods for differences in restricted mean lifetimes using pseudo-observations.
    Choi S; Choi T; Lee HY; Han SW; Bandyopadhyay D
    Pharm Stat; 2022 Nov; 21(6):1185-1198. PubMed ID: 35524651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmented estimation for t-year survival with censored regression models.
    Zheng Y; Cai T
    Biometrics; 2017 Dec; 73(4):1169-1178. PubMed ID: 28294286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-parametric estimation of transition probabilities in non-Markov multi-state models: The landmark Aalen-Johansen estimator.
    Putter H; Spitoni C
    Stat Methods Med Res; 2018 Jul; 27(7):2081-2092. PubMed ID: 29846146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
    Latimer NR; White IR; Abrams KR; Siebert U
    Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score.
    Sugihara M
    Pharm Stat; 2010; 9(1):21-34. PubMed ID: 19199275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A sensitivity analysis approach for the causal hazard ratio in randomized and observational studies.
    Axelrod R; Nevo D
    Biometrics; 2023 Sep; 79(3):2743-2756. PubMed ID: 36385393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consistent inverse probability of treatment weighted estimation of the average treatment effect with mismeasured time-dependent confounders.
    Yan Y; Ren M
    Stat Med; 2023 Feb; 42(4):517-535. PubMed ID: 36513267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of dynamic treatment regimes via inverse probability weighting.
    Hernán MA; Lanoy E; Costagliola D; Robins JM
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):237-42. PubMed ID: 16611197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
    Stegherr R; Schmoor C; Beyersmann J; Rufibach K; Jehl V; Brückner A; Eisele L; Künzel T; Kupas K; Langer F; Leverkus F; Loos A; Norenberg C; Voss F; Friede T
    Trials; 2021 Jun; 22(1):420. PubMed ID: 34187527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improve efficiency and reduce bias of Cox regression models for two-stage randomization designs using auxiliary covariates.
    Yang X; Zhou Y
    Stat Med; 2017 May; 36(11):1683-1695. PubMed ID: 28183157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.
    Conlon AS; Taylor JM; Sargent DJ
    Biometrics; 2015 Jun; 71(2):460-8. PubMed ID: 25585942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of two-phase sampling data with semiparametric additive hazards models.
    Sun Y; Qian X; Shou Q; Gilbert PB
    Lifetime Data Anal; 2017 Jul; 23(3):377-399. PubMed ID: 26995733
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.